Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic NK Cells + Trastuzumab/Pertuzumab in Refractory HER2+ Breast Cancer
NCT05385705Phase 1Terminated
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- May 2022
- Primary completion
- Jul 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK cell therapy (Anhui Provincial Hospital) in HER2-positive breast cancer, sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Nature and frequency of Adverse Events at 6 months, Nature and frequency of Serious Adverse Events at 6 months and 2 more. Started May 2022; status: terminated.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05385705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385705.